| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2397 |
| Trial ID | NCT04456023 |
| Disease | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Withdrawn |
| Title | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) |
| Year | 2020 |
| Country | Switzerland |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019C2203 |
| Cohort 1 | |||||||||||
|
|||||||||||